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Abstract
Drug therapeutic efficiency and development of unfavorable pharmacologic responses as well as the disease predisposition 
are caused first of all by patient’s genetic features. Genetic variations in genes encoding drug-metabolizing enzymes and transporter 
proteins are essential to understand the ethnic differences in disease occurrence, development, prognosis, therapeutic response and 
toxicity of drugs. For that reason, it is necessary to establish the normative frequency distribution of genotypes and alleles of these 
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genes in a particular population. Data on frequency of pharmacogenetic polymorphisms in the of Belarus population are limited. The 
goal of our investigation was to analyze the frequency distribution of genotypes and alleles of genes encoding drug-metabolizing 
enzymes (CYP1А2, CYP2D6 – I phase; GSTs, NAT2 – II phase) and transporter protein MDR1 in the population of Belarus and 
comparisons with other ethnic populations. Our results indicate that clinically important genes are genetically highly variable and 
differ considerably between populations. Differences in allele frequencies across continents should be considered when designing 
clinical trials of new drugs continents should be considered when designing clinical trials of new drugs.
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1. Introduction
One of the important problems of drug therapy is variability of patients’ responses to the 
drug used. Heterogeneity of organism reactions is also observed when taking vitamins and other 
bracing products used for correcting a functional state of a healthy human, improving physical 
efficiency and for recovering organism after endured diseases. As a result of applying the same 
pharmacologic preparation, the absence of a therapeutic effect is observed in same people and 
various complications (from slight fatigue to serious health disorders) emerge in others. At present 
many causes, which underlie interindividual differences in a pharmacologic response (sex, age, 
weight, pattern of a disease course, concomitant pathology, etc.), are known [1]. However, genetic 
distinctions of a patient are the most important stable factor determining kinetics of metabolic 
transformations of drugs in organism and heterogeneity of individual’s reaction to a drug [2, 3]. 
Such distinctions are realized via polymorphic sites of protein genes involved in drug pharmaco-
kinetics and pharmacodynamics. According to an original conception of pharmacologic metrology 
of academician L. A. Piruzian, an individual human response to drug application is determined by 
a “starting state” of enzyme systems of chemical compound (xenobiotics) metabolism [4]. Genet-
ic polymorphism of xenobiotic biotransformation enzymes results in differences in their activity 
from several times to scores of times and hundred times. At present regular search for and iden-
tification of functionally important polymorphisms of drug metabolism genes are under way for 
conducting pharmacogenetic testing (PT) since it is considered, at a given moment, one of the most 
important technologies in personalized medicine [5]. The PT results will allow a physician to select 
a drug and conditions of its dosage individually for every patient providing maximum efficiency 
and safety of drug therapy.
However, it should be taken into consideration that the occurrence frequency of allelic vari-
ants in drug metabolism genes varies greatly in different ethnic groups particularly belonging to 
diverse races (from 0 to 50 %) [6–8]. That’s why it is necessary to determine frequencies of allelic 
variants in the given genes in a particular population as far as it is obvious that PT introduction for 
certain genes will be advantageous only in that case when allelic variants of this genes occur often 
enough in the population (above 1 %). 
2. Aim
The goal of our investigation was to analyze the frequency distribution of genotypes and al-
leles of genes encoding drug-metabolizing enzymes (CYP1А2, CYP2D6 – I phase; GSTs, NAT2 – 
II phase) and transporter protein MDR1 in the population of Belarus and comparisons with other 
ethnic populations.
3. Materials and methods
The study population consisted of 538 persons without oncopathology (282 men and 
256 women). All participants were Caucasian from Belarus. Written informed consent was ob-
tained from all individuals before enrolment in the study. 
As for the age of the examined persons, the sample was divided into two groups: “under 
50 years” – 322 persons and “above 50 years” – 216 persons; smoking status was known in 302 per-
sons (109 smokers and 193 non-smokers). 
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DNA was isolated from peripheral blood lymphocytes by phenol-chloroform extraction.
We genotyped 9 SNPs in six genes involved in the hormone metabolism CYP2D6 
(rs3892097), CYP1A2 (rs762551), GSTT1 (deletion), GSTM1 (deletion), GSTP1 (rs1695), NAT2 
(rs1799929, rs1799930, rs1799931) and MDR1 (rs1045642). Characteristics of the polymorphisms 
are listed in Table 1.
Table 1
Characteristic of the polymorphisms genotyped in this study
Gene symbol rs no Nucleotide  substitution SNP function
a Protein effect Locationb MAFc
CYP1A2 rs762551 С734А intron variant – 15:74749576 0.37
CYP2D6 rs3892097 1846G>A splicing defect 22:42128945 0,17
GSTT1 – ins/del deletion deleted 22q11.23 –
GSTM1 – ins/del deletion deleted 1p13.3 –
GSTP1 rs1695 A313G missense I105V 11:67585218 0,35
NAT2 rs1799929 481C>T synonymous L161L 8:18400484 0,26
NAT2 rs1799930 590G>A missense R197Q 8:18400593 0,26
NAT2 rs1799931 857G>A missense G286E 8:18400860 0.08
MDR1 rs1045642 3435C>T synonymous I1145I 7:87509329
Note: a – According to the Single Nucleotide Polymorphism database (dbSNP); b – Based on UCSC Human Genome 
Browser, human reference sequence (GRCh38); c – MAF, minor allele frequency, according to dbSNP
Genotyping for CYP1А2, CYP2D6, GSTP1, NAT2 and MDR1 genes was performed using a 
polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) assay. Following 
amplification, PCR products were digested with ApaI (rs762551), MvaI (rs3892097), Alw26I (rs1695), 
KpnI (rs1799929), TaqI (rs1799930), BamHI (rs1799931), MboI (rs1045642) (Fermentas, Lithuania). 
The GSTT1 and GSTM1 gene polymorphisms were examined using multiplex PCR out according to 
the technique described earlier [9].
The Hardy-Weinberg equilibrium for SNPs was tested with the Pearson’s χ2 test. The anal-
ysis comparing genetic and allelic frequencies among ethnic groups was performed using χ2 tests. 
An odds ratio (OR) with a 95 % confidence interval (CI) was applied to assess the genetic associa-
tions by sex, age, smoking status. All statistical analyses were two-sided, and P<0.05 was consid-
ered as statistically significant. Statistical analysis of the material was carried out using SNPStats 
program (http://bioinfo.iconcologia.net/SNPstats_web) and Statistica 6.0.
4. Results 
Genotype distributions of the polymorphisms were in the Hardy-Weinberg equilibrium, 
only for rs762551 HWE p-values was < 0,05.
Table 2 presents the data on distribution of alleles and genotypes rs762551 polymorphism 
of CYP1A2 gene depending on sex, age and smoking status in the population of Belarus. On the 
population studied, the genotype СС occurs in 6,5 %, СА – 48,8 % and АА – 44,7 %. Analysis of 
the relationship between the frequency CYP1A2 genotype and allele distribution and sex, age and 
smoking status has not revealed any significant difference.
Table 3 presents distribution of CYP1A2 genotype and allele frequencies in various popula-
tions. The frequency of the mutant allele А in Belarus did not differ from that in the European and 
was significantly higher than in the Japanese population.
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Table 2
Distribution of CYP1A2 genotype and allele frequencies in the population of Belarus
Group
Genotype Allele
АА СА СС А С
n % n % n % n % n %
In all 240 44,7 262 48,8 35 6,5 742 69,0 332 31,0
Men
Women
114
126
40,4
49.4
147
115
52,1
45,1
21
35
7,5
5.5
375
367
66,0
72,0
189
143
34,0
28,0
Under 50 years
Above 50 years
144
96
44,9
44,4
152
110
47,4
50,9
25
10
7,8
4,6
440
302
69,0
70,0
202
130
31,0
30,0
Smokers
Non-smokers
53
87
48,6
45.1
50
94
45,9
48,7
6
12
5,5
6,2
156
268
72,0
69,0
62
118
28,0
31,0
Table 3
Genotype and allele frequencies (%) of rs762551 polymorphism CYP1A2 gene in some populations
Country In all, n
Genotype Allele
p-valuea
АА СА СС А С
Belarus 537 44,7 48,8 6,5 70,0 30,0 –
Germany [13] 722 41,9 40,9 7,2 72,4 27,6 0,07
Japan [14] 403 40,4 46,2 13,4 63,5 36,5 <0,05
USA [15] 333 49,0 41,0 10,0 69,5 30,5 0,85
Note: a – p-value for comparison between the population of Belarus and selected populations 
The frequency of the genotype АА rs3892097, determining complete absence of the CYP2D6 
enzyme activity, was 6,7 % in the population of Belarus (Table 4). The genotype GA occurred in 
35,5 % of the examined persons and 57,8 % were the carriers of the genotype GG. Analysis of 
the relationship between genotype and allele frequency distributions of rs3892097 polymorphism 
and sex and smoking status has not revealed any significant difference. There was a difference 
in the allelic and genotypic distribution between the group of persons under 50 years of age and 
persons above 50 years. The frequency of GG genotype rs3892097 in persons above 50 years 
was significantly higher and the combined AG+AA genotype frequency was lower than in per-
sons under 50 years. OR for dominant model GG vs GA+AA was 0,62 CI95 %:0,43–0,91; p=0,012, 
p log-additive=0,026.
Table 4
Genotype and allele frequencies of rs3892097 polymorphism in the population of Belarus
Group
Genotype Allele
GG GА AA G A
n % n % n % n % n %
In all 311 57,8 191 35,5 36 6,7 813 76,0 263 24
Men
Women
165
146
58,5
57,1
98
93
34,8
36,3
19
17
6,7
6,6
428
385
76,0
75,0
136
127
24,0
25,0
Under 50 yearsa
Above 50 years 
172
139
64,3
53,4
127
64
39,4
29,6
23
13
7,1
6,1
471
342
73,0
79,0
173
90
27,0
21,0
Smokers 
Non-smokers
67
127
61,5
65,8
34
56
31,2
29,0
8
10
7,3
5,2
168
310
77,0
80,0
50
76
23,0
20,0
Note: a – significant difference between the group of persons under 50 years of age and persons above 50 years
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The data on GSTs-gene genotyping in the population of Belarus are given in Table 5. The 
frequency of the “null genotype” for genes GSTT1 and GSTM1 was 14,9 % and 43,7 % respectively, 
that is consistent with the occurrence frequency of these genotypes in the Europeoids. No signifi-
cant differences were revealed in the occurrence frequency of null-genotyping depending on age, 
sex and smoking status. 
Table 5
Distribution of GSTs genotype and allele frequencies in the population of Belarus
Genotype
In all
Sex Age Smoking status
men women <50 >50 smokers Non-smokers
n % n % n % n % n % n % n %
GSTM1 (present)
GSTM1 (null)
303
235
56,3
43,7
165
117
58,5
41,5
138
118
53,9
46,1
171
151
53,1
46,9
132
84
61,1
38,9
66
43
60,5
39,5
106
87
54,9
45,1
GSTT1 (present)
GSTT1 (null)
458
80
85,1
14,9
238
44
84,4
15,6
220
36
85,9
14,1
276
46
85,7
14,3
182
34
84,3
15,7
95
14
87,2
12,8
161
32
83,4
16,6
GSTP1
AA
GA
GG
Allele A
Allele G
258
242
38
758
318
48,0
45,0
7,0
70,0
30,0
134
124
24
392
172
47,5
44,0
8,5
70,0
30,0
124
118
14
366
146
48,4
46,1
5,5
71,0
29,0
149
150
23
448
196
46,3
46,6
7,1
70,0
30,0
109
92
15
310
122
50,5
42,6
6,9
71,8
28,2
45
54
10
144
74
41,3
49,5
9,2
66,0
34,0
94
89
10
277
109
48,7
46,1
5,2
71,8
28,2
Analysis of rs1695 polymorphism in the population of Belarus has shown that distribution 
of genotype frequencies was as follows: the genotype АА – 48,0 %; the genotype GA – 45,0 % and 
the genotype GG – 7,0 %. No significant differences were also revealed for distribution of GSTP1 
genotypes depending on age, sex and smoking status. On the studied group, the frequency of the 
mutant allele was comparable with frequencies in representatives of the European population and 
was lower than in the Afro-Americans and higher than in the Chinese population (Table 6).
Table 6
Genotype and allele frequencies (%) of rs1695 polymorphism in different ethnic groups
Population In all, n Genotype Allele p-valuea
АА GA GG А G
Belarus population 538 48,0 45,0 7,0 70,0 30,0
The Europeoids [16] 287 42,0 51,0 7,0 67,0 33,0 0,76
The Afro-Americans [17] 120 31,0 53,0 16,0 58,0 42,0 <0,05
The Chinese [18] 1211 67,0 30,0 3,0 82,0 18,0 <0,05
Note: a – p-value for comparison between the population of Belarus and selected populations 
We have carried out NAT2 genotyping for three polymorphic sites: rs1799929, rs1799930 and 
rs1799931. The frequency of homozygous mutation (ТТ) in the position C481T (rs1799929) was 19,7 % 
in the studied group, homozygous substitution (АА) in the position G590A (rs1799930) occurred in 
8,0 %. It should be noted that no individuals with the genotype АА were detected during studying 
rs1799931 polymorphism. Analysis of the relationship between the frequency NAT2 genotype and 
allele distribution and sex and age has not revealed any significant difference. Significant differences 
were found in the distribution of polymorphic variants of rs1799929 and rs1799930 polymorphisms 
between smokers and nonsmokers (Table 7). The results of our study showed an association between 
the carriers of CC genotype rs1799929 polymorphism and GG genotype rs1799930 polymorphism 
(dominant model) and cigarette smoking (p-value=0,019 and 0,022 respectively). 
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Table 7
Genotype frequencies of rs1799929 and rs1799930 polymorphisms in smokers and nonsmokers
Genotype Nonsmokers Smoker OR (95 % CI) P-value
rs1799929
CC 37 (19,2 %) 34 (31,2 %) 1,00
0,019
CT+TT 156 (80,8 %) 75 (68,8 %) 0,52 (0,30–0,90)
Log-additive – – 0,73 (0,51–1,05) 0,088
rs1799930
GG 73 (37.8 %) 56 (51.4 %) 1,00
0,022
GA+AA 120 (62.2 %) 53 (48.6 %) 0,58 (0.36–0.93)
Log-additive 0,69 (0,47–1,03) 0,065
The examined individuals were divided into “fast” and “slow” acetylators according to accept-
ed approaches [19]. The holders of three dominant alleles in the homozygous state (481СС, 590GG 
и 857GG) as well as those in whom only one of the three studied genotypes was in the heterozygous 
state (481СТ, 590GG, 857GG; 481СС, 590GА, 857GG и 481СС, 590GG, 857GА) were attributed to 
“fast” acetylators. All the rest of the genotype combinations formed the group of “slow” acetylators. 
The frequency of “fast” acetylators was 38,5 % in the population of Belarus and that of “slow” acetyl-
ators – 61,5 % (Table 8). The observed ratio of “fast” and “slow” acetylators differed significantly 
from distribution of acetylators in the populations of Germany and Italy.
Table 8
The frequency (%) of “fast” and “slow” acetylators in various populations
Country “Fast” acetylators “Slow” acetylators p-valuea
Belarus 38,5 61,5
Germany [20] 43,2 56,8 <0,05
Italy [21] 48,2 51,8 <0,05
Sweden [22] 40,5 59,5 0.07
USA [23] 37,9 62,1 0,42
Note: a – p-value for comparison between the population of Belarus and selected populations 
Distribution of the MDR1 genotype in the population of Belarus (Table 9) was as follows: 
СС – 21,4 %, СТ – 51,7 %, ТТ – 26,9 %. 
Table 9
Genotype and allele frequencies of rs1045642 polymorphism in the population of Belarus
Groups
Genotype Allele
CC CT TT C T
n % n % n % n % N %
In all 115 21,4 278 51,7 145 26,9 508 47,0 568 53,0
Men
Women
66
49
23,4
19,1
144
134
51,1
52,3
72
73
25,5
28,5
276
232
49,0
45,0
288
280
51,0
55,0
Under 45 years
Above 45 years
70
45
21,7
20,8
162
116
50,3
53,7
90
55
27,9
25,5
302
206
47,0
48,0
342
226
53,0
52,0
Smokers
Nonsmokers
26
41
23,9
21,2
51
101
46,8
52,3
32
51
29,4
26,4
103
183
47,0
47,0
115
203
53,0
53,0
No significant differences in age, sex and smoking status were revealed for distribution of 
MDR1 genotypes. 
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5. Discussion
Nowadays polymorphism of genes encoding enzymes of drug metabolism I phase, in partic-
ular isoenzymes of cytochrome Р-450 (CYP2D6, CYP1A2) is actively studied [7, 10, 11].
The CYP1A2 enzyme, a member of the cytochrome P450 superfamily of proteins is a key 
component of monooxygenases. CYP1A2 catalyzes the metabolic activation of a variety of aryl- 
and heterocyclic amines such as 2-aminoanthracene and 2-acetylaminofluoren. Above 40 genetic 
polymorphisms of the CYP1А2 enzyme were indentified but few of them have been reported to 
affect the activity of CYP1A2 [12]. The CYP1A2*1F polymorphism (rs762551, –163С<A) in the 
first intron CYP1A2 gene is one of the most common studied variants. For this polymorphism was 
shown association with the enzyme activity: the allele А determines higher activity of the CYP1A2 
enzyme and the allele С – low activity.
CYP2D6 is an important polymorphic phase- I drug-metabolism enzyme and plays an im-
portant role in the metabolism of a variety of drugs and environmental compounds. CYP2D6 is 
involved in metabolism of more than 20 % drugs (for instance, debrisoquine, antidepressants, be-
ta-blockers et al [5, 7, 10, 24]. The CYP2D6 gene located at chromosome 22q 13.2 is one of the most 
polymorphic CYP450 genes. At present above 70 alleles of this gene are known, although multiple 
allele identified no function [25]. CYP2D6*3, CYP2D6*4, CYP2D6*5, and CYP2D6*6 are report-
ed to be associated with enzymatic activity and varies from complete absence (“poor” metabolizer) 
to ultra-fast metabolism (“fast” metabolizer). However, it was shown that 75 % of “poor” metabo-
lizers were carriers of CYP2D6*4 (rs3892097,1846G>A) polymorphism [24]. 
The frequency of AA genotype rs3892097, determining complete absence of the enzyme 
activity, varied greatly in different ethnic groups: in the Europeans – 5–10 %, the Afro-Ameri-
cans – 1,8 %, the Chinese – 1 % [7, 11, 26,2 7]. The frequency of the mutant allele А (24,0 %) and 
AA genotype (6,7 %) of rs3892097 in Belarus did not differ from that in the European populations.
Glutathione-S-transferase (GST) and N-acetyltransferase (NAT) are key enzymes of the 
second phase in biotransformation. Out of these enzymes glutathione transferases of μ class 
(GSTM1), θ class (GSTТ1) and π class (GSTP1) are the most studied.
GSTМ1 and GSTТ1 polymorphisms are caused by the presence of extensive deletion in the 
coding region (“null genotype”). It is important to note that about 50 % of the Europeans have 
homozygous deletion of GSTM1 gene and 10–20 % – homozygous deletion of GSTТ1 gene [28]. 
Synthesis of the corresponding protein product does not occur at the given mutations. The presence 
of the “null genotype”, even if for one of these genes (GSTM1 or GSTТ1), is related to an increase 
in risk of multifactorial disease development. In recent years the data on association of GSTM1 and 
GSTТ1 with development of unfavorable reactions after chemotherapy came to light [28].
The enzyme glutathione S-transferase of π class (GSTP1) is involved in metabolism of wide 
spectrum xenobiotics including drugs. The rs1695 polymorphism in the 5th exon of GSTP1 gene, man-
ifesting itself in substitution of isoleucine 105 by valine (Ile105Val), is associated with development of 
drug resistance in oncologic disease treatment. Watson et al. showed that allele G (Ile/Val and Val/Val) 
were characterized by a reduced conjugation activity of the enzyme as compared to individuals with the 
genotype АА (Ile/Ile) [16]. 
N-acetyltransferase 2 (NAT2) is a major enzyme of acetylating xenobiotics with the pri-
mary aromatic and hydrazine structure. NAT2 metabolizes and detoxifies xenobiotics such as 
caffeine, tobacco smoke, pesticides, and drugs [29, 30] Metabolic acetylation polymorphism, 
which manifests itself by the presence of “fast” and “slow” acetylators in the population of phe-
notypes, is known. Thirteen point mutations, in the coding region NAT2, which form 36 alleles 
in different combinations is its bases [31]. Pronounced ethnic differences are a distinction of 
NAT2 polymorphism. Among populations of Europe and North America, 40–70 % are “slow” 
acetylators whereas among populations of the Pacific shore of Asia (the Japanese, the Chinese, 
Koreans) only 10–30 % of representatives are “slow” acetylators [19, 31]. Individual and ethnic 
differences in the acetylation rate exert an effect on development of unfavorable reactions when 
taking some drugs.
Our study showed an association between the carriers of CC genotype rs1799929 polymor-
phism and GG genotype rs1799930 polymorphism and cigarette smoking. It is possible that the 
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carrier of CC genotype rs1799929 and GG genotype rs1799930 (“fast” acetylator status) reduces a 
detrimental effect of smoking.
In recent years the influence of Р-glycoprotein, encoded by MDR1 gene, on drug pharmok-
inetics was studied. P-glycoprotein is involved in elimination of a lot of drugs into extracellular 
space [6, 32]. The level of enzyme expression causes drug concentration in cell: the higher is ex-
pression of an active transporter, the faster substrate or its metabolites are removed from cell and the 
quicker their concentration is reduced. The rs1045642 polymorphism (3435С<Т) was revealed to 
be associated with the level of Р-glicoprotein expression: СС-homozygotes are characterized with 
a high level of Р-glicoprotein expression, ТT-homozygotes – with a low level and heterozygotes 
СT – with an intermediate level [33]. The frequency of С3435Т substitution differed greatly among 
ethnics groups: the frequency of the ТT genotype in the European populations – 17–28 % [34–36], 
in the Iranians – 19 % [37], in the Japanese – 12 % [38], in the Afro-Americans – 1 % [35]. The 
genotype frequency of rs1045642 in Belarus corresponded to that in the European population and 
was significantly higher than in the Japanese and in the Afro-Americans.
No significant differences in sex were revealed for distribution of MDR1 genotypes. How-
ever, it is known from the literature data that Р-glycoprotein expression was higher by a factor of 
2,4 in men than in women. Therefore pharmacogenetic investigations on metabolism of drugs, 
being Р-glycoprotein substrate, should be performed taking into account sex differences [39, 40]. 
Application of such an approach allows differentiated prescription of drug therapeutic dose for men 
and women.
6. Conclusion
Study on genetic polymorphism of biotransformation enzymes involved in drug metabolism 
was first carried out in the population of Belarus. Our results indicate that clinically important 
genes are genetically highly variable and differ considerably between populations. These inves-
tigations can underlie an individual genetic passport which enables correction of treatment (drug 
selection and conditions of its dosage) in view of individual features of patients that will make 
pharmacotherapy more effective and safe. It should be emphasized that a genetic component of 
drug efficiency and/or toxicity can be determined before starting treatment.
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